METTL14 Antibody [A8N22] Datasheet

Biological Description

Specificity	METTL14 Antibody [A8N22] detects endogenous levels of total METTL14 protein.
Background	Methyltransferase‑like protein 3 (METTL3) is the catalytic core of an N6‑adenosine methyltransferase complex that installs m6A marks on a broad spectrum of RNA transcripts, where it functions as a key writer of the epitranscriptomic code that influences mRNA splicing, processing, translation efficiency, stability, and primary miRNA maturation. METTL3 directly catalyzes the transfer of methyl groups to adenosine residues, whereas its partner METTL14 acts as an RNA‑binding scaffold that helps position the substrate and stabilize the active conformation of the methyltransferase module, so that together they define the substrate specificity and methylation landscape of the complex. The complex is further regulated by the Wilms’ tumor 1‑associating protein (WTAP), which directs the METTL3–METTL14 core to nuclear speckles, specialized subnuclear domains enriched in splicing factors and RNA‑processing machinery, thereby coupling m6A deposition to cotranscriptional and early post‑transcriptional regulation. Through these mechanisms, METTL3‑dependent m6A modification modulates the expression of genes involved in circadian rhythm, embryonic stem cell self‑renewal, immune tolerance, meiotic progression, and fertility, underscoring its role in integrating transcriptional and post‑transcriptional control across diverse developmental and homeostatic pathways. METTL3 is frequently overexpressed in lung adenocarcinoma and other malignancies, where it enhances tumor‑cell growth, survival, and invasion by stabilizing or promoting the translation of oncogenic transcripts and by altering the abundance and activity of key signaling and metabolic regulators.

Specificity

METTL14 Antibody [A8N22] detects endogenous levels of total METTL14 protein.

Background

Methyltransferase‑like protein 3 (METTL3) is the catalytic core of an N6‑adenosine methyltransferase complex that installs m6A marks on a broad spectrum of RNA transcripts, where it functions as a key writer of the epitranscriptomic code that influences mRNA splicing, processing, translation efficiency, stability, and primary miRNA maturation. METTL3 directly catalyzes the transfer of methyl groups to adenosine residues, whereas its partner METTL14 acts as an RNA‑binding scaffold that helps position the substrate and stabilize the active conformation of the methyltransferase module, so that together they define the substrate specificity and methylation landscape of the complex. The complex is further regulated by the Wilms’ tumor 1‑associating protein (WTAP), which directs the METTL3–METTL14 core to nuclear speckles, specialized subnuclear domains enriched in splicing factors and RNA‑processing machinery, thereby coupling m6A deposition to cotranscriptional and early post‑transcriptional regulation. Through these mechanisms, METTL3‑dependent m6A modification modulates the expression of genes involved in circadian rhythm, embryonic stem cell self‑renewal, immune tolerance, meiotic progression, and fertility, underscoring its role in integrating transcriptional and post‑transcriptional control across diverse developmental and homeostatic pathways. METTL3 is frequently overexpressed in lung adenocarcinoma and other malignancies, where it enhances tumor‑cell growth, survival, and invasion by stabilizing or promoting the translation of oncogenic transcripts and by altering the abundance and activity of key signaling and metabolic regulators.

Usage Information

Application

WB

Dilution

WB

1:1000

Reactivity

Human, Mouse, Rat, Monkey

Source

Rabbit Monoclonal Antibody

MW

65 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/34996469/
https://pubmed.ncbi.nlm.nih.gov/41139780/

Application Data

WB

Validated by Selleck

Lane 1: NCCIT, Lane 2: F9, Lane 3: COS-7